Studies have shown that orlistat treatment reduces the enzyme activity and expression of CPT2 and has a stronger therapeutic effect on growth inhibition and apoptosis in hepatocellular carcinoma after combination treatment with paclitaxel [134]. Here, CPT2 is linked to hepatocellular carcinoma.